Third, for modern treatment of CRC, routine testing of microsatellite instability (MSI) and RAS/BRAF mutation status has been recommended since 2014, as these have been confirmed to be prognostic factors for CRC patients. The gene discussed is BRAF; the disease is colorectal carcinoma.